glp-1 eating disorder obesity drugs and disorders are not well understood yet : NPR Glucagon-like peptide-1 medicines in neurological

PMID 30835257

The GLP-1R/GcgR dual-agonist BI 456906 developed by Boehringer-Ingelheim achieves body weight reductions of 5.8% over 6 weeks and 13.8% over 16 weeks, at the maximal dosages within a multiple rising dose phase Ib clinical study [96]

Supplements provide a baseline of support while IV therapy addresses specific needs or situations where faster or more reliable delivery is required

D-Carnitine D-Carnitine is not a beneficial form of carnitine and should not be used as a dietary supplement

Across the trials, the drugs were linked to reductions in binge eating severity, less disinhibited eating (where people struggle to resist food despite not being physically hungry), and fewer episodes of feeling out of control while eating

McCall McPhereson: Yeah, so when people have lost true endogenous thyroid function, when their thyroid gland is no longer functioning, adequately secreting hormones